WO2004067027A3 - Osteogenic composition - Google Patents

Osteogenic composition Download PDF

Info

Publication number
WO2004067027A3
WO2004067027A3 PCT/IB2004/000577 IB2004000577W WO2004067027A3 WO 2004067027 A3 WO2004067027 A3 WO 2004067027A3 IB 2004000577 W IB2004000577 W IB 2004000577W WO 2004067027 A3 WO2004067027 A3 WO 2004067027A3
Authority
WO
WIPO (PCT)
Prior art keywords
amount
synergistic amount
bmp
pharmaceutically acceptable
acceptable carrier
Prior art date
Application number
PCT/IB2004/000577
Other languages
French (fr)
Other versions
WO2004067027A9 (en
WO2004067027A2 (en
Inventor
Franz Weber
Original Assignee
Univ Zuerich
Franz Weber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich, Franz Weber filed Critical Univ Zuerich
Priority to BR0407178-6A priority Critical patent/BRPI0407178A/en
Priority to JP2006502481A priority patent/JP2006519782A/en
Priority to CA002513712A priority patent/CA2513712A1/en
Priority to EP04706251A priority patent/EP1589989A2/en
Priority to AU2004208569A priority patent/AU2004208569B2/en
Publication of WO2004067027A2 publication Critical patent/WO2004067027A2/en
Publication of WO2004067027A3 publication Critical patent/WO2004067027A3/en
Publication of WO2004067027A9 publication Critical patent/WO2004067027A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The present invention relates to pharmaceutical composi-tions containing a synergistic amount of at least one bone morphogenetic protein (BMP) and a synergistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier, such as a biodegradable polymer. The present invention further relates to methods of treating or-thopaedic and dental, including periodontal, diseases by simultaneously administering a synergistic amount of at least one bone morphogenetic protein (BMP) and a syner-gistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier to patients in need of such treatment.
PCT/IB2004/000577 2003-01-30 2004-01-29 Osteogenic composition WO2004067027A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BR0407178-6A BRPI0407178A (en) 2003-01-30 2004-01-29 Osteogenic Pharmaceutical Composition
JP2006502481A JP2006519782A (en) 2003-01-30 2004-01-29 Pharmaceutical composition
CA002513712A CA2513712A1 (en) 2003-01-30 2004-01-29 Osteogenic composition
EP04706251A EP1589989A2 (en) 2003-01-30 2004-01-29 Osteogenic composition
AU2004208569A AU2004208569B2 (en) 2003-01-30 2004-01-29 Osteogenic composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/354,856 2003-01-30
US10/354,856 US7074412B2 (en) 2003-01-30 2003-01-30 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
WO2004067027A2 WO2004067027A2 (en) 2004-08-12
WO2004067027A3 true WO2004067027A3 (en) 2004-09-16
WO2004067027A9 WO2004067027A9 (en) 2004-10-07

Family

ID=32770436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000577 WO2004067027A2 (en) 2003-01-30 2004-01-29 Osteogenic composition

Country Status (9)

Country Link
US (1) US7074412B2 (en)
EP (1) EP1589989A2 (en)
JP (1) JP2006519782A (en)
KR (1) KR20050105446A (en)
CN (1) CN100490893C (en)
AU (1) AU2004208569B2 (en)
BR (1) BRPI0407178A (en)
CA (1) CA2513712A1 (en)
WO (1) WO2004067027A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7189409B2 (en) * 2004-03-09 2007-03-13 Inion Ltd. Bone grafting material, method and implant
US20060258578A1 (en) * 2005-05-10 2006-11-16 The University Of Zurich Pharmaceutical composition
KR100865759B1 (en) * 2007-05-07 2008-10-29 울산대학교 산학협력단 Process for preparing recombinant human bmp-2 employing gene coding for human bmp-2
KR100932945B1 (en) * 2009-01-16 2009-12-21 원광대학교산학협력단 Solid scaffold formed with bone powder and fibrin glue
KR100932947B1 (en) * 2009-01-16 2009-12-21 원광대학교산학협력단 Composition for reproduction of bone containing angiogenin
KR100932948B1 (en) * 2009-01-16 2009-12-21 원광대학교산학협력단 Solid scaffold formed with bone powder and fibrin glue, containing bmp-2
US20150335400A1 (en) * 2009-06-17 2015-11-26 The Trustees Of Columbia University In The City Of New York Tooth scaffolds
JP2012530548A (en) 2009-06-17 2012-12-06 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Tooth scaffolding
WO2012101173A1 (en) * 2011-01-26 2012-08-02 Universität Zürich N-methyl-2-pyrrolidone for prevention and treatment of bone loss
WO2017019832A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Methods and compositions using repair cells and cationic dyes
WO2017019833A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Compositions containing repair cells and cationic dyes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
WO2003060076A2 (en) * 2001-12-21 2003-07-24 Centerpulse Biologics, Inc. Povidone-containing carriers for polypeptide growth factors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
AU3699900A (en) * 1999-02-16 2000-09-04 Sulzer Biologics, Inc. Device and method for regeneration and repair of cartilage lesions
US6926903B2 (en) 2001-12-04 2005-08-09 Inion Ltd. Resorbable polymer composition, implant and method of making implant
US20030105530A1 (en) 2001-12-04 2003-06-05 Inion Ltd. Biodegradable implant and method for manufacturing one

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
WO2003060076A2 (en) * 2001-12-21 2003-07-24 Centerpulse Biologics, Inc. Povidone-containing carriers for polypeptide growth factors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDRIANO KIRK P ET AL: "Preliminary in vivo studies on the osteogenic potential of bone morphogenetic proteins delivered from an absorbable puttylike polymer matrix", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, WILEY, NEW YORK, NY, US, vol. 53, 2000, pages 36 - 43, XP002971940, ISSN: 0021-9304 *

Also Published As

Publication number Publication date
CN100490893C (en) 2009-05-27
US7074412B2 (en) 2006-07-11
WO2004067027A9 (en) 2004-10-07
BRPI0407178A (en) 2006-02-07
AU2004208569A1 (en) 2004-08-12
US20040152627A1 (en) 2004-08-05
KR20050105446A (en) 2005-11-04
EP1589989A2 (en) 2005-11-02
WO2004067027A2 (en) 2004-08-12
JP2006519782A (en) 2006-08-31
AU2004208569B2 (en) 2008-07-31
CA2513712A1 (en) 2004-08-12
CN1761481A (en) 2006-04-19

Similar Documents

Publication Publication Date Title
WO2004067027A3 (en) Osteogenic composition
WO2004019884A3 (en) Agents and methods for enhancing bone formation
MXPA02006679A (en) Pharmaceutical composition.
WO2004006858A3 (en) Compounds, compositions, and methods employing same
ATE357193T1 (en) BIOACTIVE LOAD-BEARING COMPOSITIONS FOR BONE COMPOUNDS
WO2002041837A3 (en) Treatment of mucositis
HUS1900037I1 (en) Oral antimicrobial pharmaceutical compositions
WO2001015715A3 (en) Composition for maintenance of bone or dental health or treatment of bone or dental disorders
CA2427227A1 (en) Lactam compound
WO2004043341A3 (en) Treatment for hemorrhagic shock
EP1783126A3 (en) N-oxides of N-phenyl-2-pyrimidine-amine derivatives
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
DK1654253T3 (en) Substituted 3-pyrrolidine indole derivatives
ATE396967T1 (en) (5-(2-HYDROXY-4-CHLOROBENZOYL)VALERIC ACID AND SALTS THEREOF, AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS CONTAINING THESE COMPOUNDS
EP2767291A3 (en) Treatment of glycogen storage disease type II
EP2392322A3 (en) Dosing regimes for trans-clomiphene
MY128362A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
EP1637132A4 (en) External preparation for athlete´s foot treatment
PL343375A1 (en) Matrix protein compositions for wound healing
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
IL149134A0 (en) Pharmaceutical compositions containing tofisopam
ATE439833T1 (en) PHARMACEUTICAL PREPARATION CONTAINING A CATECHINE, ASCORBIC ACID, PROLINE AND LYSINE FOR THE TREATMENT OF NEOPLASTIC DISEASES
ATE234835T1 (en) SUSPENSIONS CONTAINING TROVAFLOXACIN FOR ORAL USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: SEQUENCE LISTING ADDED (1 PAGE)

WWE Wipo information: entry into national phase

Ref document number: 2513712

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020057014086

Country of ref document: KR

Ref document number: 2006502481

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004208569

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004706251

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004208569

Country of ref document: AU

Date of ref document: 20040129

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004208569

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004805562X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004706251

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057014086

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0407178

Country of ref document: BR

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)